Melanocortins stimulate the central oxytocin systems that are involved in regulating social behaviours. Alterations in central oxytocin have been linked to neurological disorders such as autism, and melanocortins have been proposed for therapeutic treatment. In the present study, we investigated how systemic administration of melanotan-II (MT-II), a melanocortin agonist, affects oxytocin neuronal activity and secretion in rats. The results obtained show that I.V., but not intranasal, administration of MT-II markedly induced Fos expression in magnocellular neurones of the supraoptic (SON) and paraventricular nuclei (PVN) of the hypothalamus, and this response was attenuated by prior I.C.V. administration of the melanocortin antagonist, SHU-9119. Electrophysiological recordings from identified magnocellular neurones of the SON showed that I.V. administration of MT-II increased the firing rate in oxytocin neurones but did not trigger somatodendritic oxytocin release within the SON as measured by microdialysis. Our data suggest that, after I.V., but not intranasal, administration of MT-II, the activity of magnocellular neurones of the SON is increased. Because previous studies showed that SON oxytocin neurones are inhibited in response to direct application of melanocortin agonists, the actions of I.V. MT-II are likely to be mediated at least partly indirectly, possibly by activation of inputs from the caudal brainstem, where MT-II also increased Fos expression.
Oxytocin released from the posterior pituitary gland plays a pivotal role in reproductive functions such as parturition and lactation. In addition, oxytocin released within the brain modulates pro-social behaviours in several species, including pair bonding, as well as maternal and sexual behaviour (1) (2) (3) . Alterations in the central oxytocin systems, including alterations in peptide structure and release, and genetic variations of the oxytocin receptor (4), have been linked to neuropsychiatric disorders such as autism spectrum disorders, anxiety and schizophrenia (5) (6) (7) (8) .
Oxytocin administration has been proposed as a potential treatment for these mental disorders (9) , although systemic oxytocin administration is not a feasible option as a result of its poor blood-brain barrier (BBB) penetration (10) . In recent years, studies in humans have suggested that oxytocin given intranasally might by-pass the BBB, although these results remain controversial (11, 12) .
An alternative approach would be to stimulate the brain to trigger the release of endogenous oxytocin (13, 14) . Oxytocin is synthesised in large amounts in magnocellular neurones of the paraventricular nuclei (mPVN) and supraoptic nuclei (SON) of the hypothalamus, and also in lesser amounts in parvocellular neurones of the PVN (pPVN). In the brain, oxytocin is released synaptically by pPVN neurones, and dendritically by magnocellular SON and PVN neurones (15) . The dendrites of magnocellular neurones contain a large number of oxytocin-and vasopressin-containing vesicles that can be released by exocytosis (16) independently of peripheral release (17) . Somatodendritic release is not specifically targeted at synapses, and the long half-life of peptides in the central nervous system and their abundance in the extracellular fluid means that, after release, they are likely to diffuse to distant targets and have prolonged behavioural effects (15, 18) .
The melanocortin a-melanocyte-stimulating hormone (a-MSH) is a potent stimulus for inducing central oxytocin release. In vitro, a-MSH mobilised intracellular calcium in SON oxytocin neurones and triggered dendritic oxytocin release and, when injected centrally, it stimulated the expression of Fos (the protein product of the immediate early gene c-fos) in magnocellular oxytocin neurones at the same time as inhibiting peripheral oxytocin secretion by decreasing the electrical activity of these neurones (19) . Interestingly, the a-MSH mediated increase in Fos expression and reduction in firing rate of magnocellular oxytocin neurones described in virgin rats (19) is suppressed in pregnant rats (20) . The actions of a-MSH are mediated through melanocortin-4 receptors (MC4R), which are expressed in the SON and PVN (21, 22) . However, similar to oxytocin, a-MSH is not able to penetrate the BBB in physiological significant amounts (23, 24) and therefore itself is not useful for systemic administration with the aim of stimulating the central oxytocin systems.
Melanotan-II (MT-II) is a synthetic heptapeptide acting on both melanocortin-3 receptors (MC3R) and MC4R. Compared to a-MSH, MT-II has been described as 'a superpotent' melanocortin agonist with a long half-life in the plasma, and its cyclic structure confers better BBB permeability (25) . Intraperitoneal (I.P.) injection of (10 mg/kg) MT-II potentiates oxytocin release in the nucleus accumbens and facilitates adult pair bonding formation through an oxytocin-dependent mechanism in prairie voles (26) . Furthermore, I .P. injection of MT-II stimulates expression of the immediate-early gene product EGR1 in oxytocin neurones and facilitates adult partner preference in female prairie voles (27) .
In the present study, we investigated the effects of I.V. and intranasal administration of MT-II on oxytocin neurones in rats. We analysed changes in the expression of Fos in neurones of the SON and PVN, as well as in the brain structures involved in the regulation of oxytocin release, such as the anterior third ventricle region (AV3V) and the nucleus tractus solitarii (NTS). We also conducted electrophysiological extracellular recordings from SON neurones in vivo, and intracerebral microdialysis and systemic blood sampling experiments, aiming to determine how MT-II affected the electrical activity of oxytocin neurones, as well as the central and peripheral release of oxytocin.
Materials and methods

Animals
Adult male Sprague-Dawley rats weighing 280-320 g, aged approximately 2 months old, were used for immunohistochemistry and in vivo microdialysis experiments. The animals had ad lib. access to food and water and were maintained under a 12 : 12 h light/dark cycle (lights on 07.00 h) at a room temperature of 20-21°C. All of the procedures were conducted on rats under deep terminal anaesthesia, in accordance with the UK Home Office Animals Scientific Procedures Act 1986, and were approved by the Ethical Committee of the University of Edinburgh.
Drugs
For I.V. injections, MT-II (American Peptide Company, Inc., Sunnyvale, CA, USA) was dissolved at 1 mg/ml in commercial 0.9% saline (B. Braun, Melsungen, Germany). For I.C.V. injections, the melanocortin antagonist SHU-9119 (Abcam Plc, Cambridge, UK) and MT-II were dissolved at a concentration of 0.33 lg/ll in artificial cerebrospinal fluid (aCSF) (Tocris Bioscience, Bristol, UK). For intranasal MT-II application, 1 or 30 lg of MT-II was dissolved in 20 ll of aCSF. For retrodialysis application, a-MSH (Sigma-Aldrich, Poole, UK) was dissolved at a concentration of 100 lM (167 ng/ll) in aCSF.
Drug administration
The rats were briefly anaesthetised using isoflurane and then sodium pentobarbital (40 mg/kg) given I.P. A polyethene cannula was inserted into the femoral vein to maintain anaesthesia by I.V. injections of sodium pentobarbital (25 mg/kg) every 40-45 min. After 2 h, MT-II (1 mg/ml/kg) or vehicle was injected I.V. (n = 12/group). After 90 min, the rats were transcardially perfused as described below.
For I.C.V. injections, a burr hole was drilled through the skull (coordinates: 0.6 mm caudal to bregma, 1.5 mm lateral to midline) and a 4.5-mm long guide cannula (Plastics One Inc., Roanoke, VA, USA) was lowered into the right cerebral ventricle under isoflurane anaesthesia. The cannula was secured in place using two stainless screws fixed to the skull and dental cement. After 4 days of recovery, the rats were anaesthetised with pentobarbital (40 mg/kg, I.P.) and the melanocortin antagonist SHU-9119 was injected (1 lg/rat, I.C.V.). Ten minutes later, MT-II (1 mg/kg) was given i.v. After 90 min, the rats were transcardially perfused.
For intranasal administration, rats were anaesthetised with sodium pentobarbital as described above. After 2 h, rats were placed in a supine position, with the head supported at 45°to the body (28,29) and 1 lg or 30 lg MT-II (dissolved in 20 ll aCSF) was given intranasally by slowly pipetting a 10-ll volume into each nostril when the rats were prone on their backs (n = 6 per group). These doses were selected as molar equivalents to doses of intranasal oxytocin used in previous studies (29) . After 90 min, the rats were transcardially perfused. Inhalation anaesthetics were not used and all the procedures were carried out under air-controlled conditions in a room in the animal unit under positive pressure to avoid stimulation of the olfactory system by unspecific odours.
Tissue collection
Rats received an overdose of pentobarbital (160 mg/kg) and were then transcardially perfused with a heparinised (20 U/ml) 0.9% saline solution followed by paraformaldehyde (PFA) 4% in 0.1 M phosphate buffer (PB). Next, the brains were removed and immersed in a solution containing 2% PFA and 15% sucrose in 0.1 M PB overnight. After this, the brains were kept in a solution containing 30% sucrose for at least 72 h. Finally, the brains were dissected, and coronal sections (40 lm) were cut using a freezing microtome. The sections including the SON, PVN, the olfactory bulb, the subfornical organ (SFO), the organum vasculosum of the lamina terminalis (OVLT) and the NTS were stored in cryoprotectant until they were processed for immunohistochemistry.
Immunohistochemistry
Standard free floating immunochemistry methods were used in the present study as described previously (29) . Sections were washed between steps in 0.1 M PB (pH 7.4). The endogenous peroxidase activity was blocked using 0.1 M PB containing 0.3% H 2 O 2 for 20 min. To avoid background staining caused by interactions of the secondary antibodies with the tissue, sections were incubated in a blocking buffer solution containing 3% normal horse serum + 0.3% Triton X-100 in 0.1 M PB. Then sections were incubated for 48 h at 4°C in c-Fos polyclonal antibody raised in rabbit (Ab5, PC38; Calbiochem, EMD Chemicals Inc., San Diego, CA, USA) diluted at 1 : 20 000 in blocking buffer. Subsequently, sections were incubated in 0.1 M PB for 1 h at room temperature in biotinylated horse anti-rabbit IgG (Vector Laboratories, Inc., Peterborough, UK) diluted 1 : 500. Then, sections were incubated for 1 h in Vectastain Elite ABC Kit (Vector Laboratories, Inc.) in accordance with the manufacturer's instructions. To visualise the Fos immunoreaction, a solution containing 0.025% diaminobenzidine, 2.5% nickel II sulphate, 0.08% ammonium chloride and 0.015% H 2 O 2 in 0.1 M Tris was used.
Double immunochemistry was performed for Fos and oxytocin. All procedures were conducted as described above. For oxytocin immunostaining, sections were incubated in mouse anti-rat PS38-oxytocin-neurophysin monoclonal antibody (30) kindly provided by Professor H. Gainer (NIH, Bethesda, MD, USA) diluted 1 : 5000. Sections were incubated in 0.1 M PB for 1 h at room temperature in biotinylated horse anti-mouse IgG antibody (Vector Laboratories, Inc.). To visualise the oxytocin immunoreaction, a solution containing 0.025% diaminobenzidine and 0.015% H 2 O 2 in 0.1 M Tris was used.
Finally, sections were mounted on gelatinised slides, air-dried for 12 h and dehydrated in increasing concentrations of ethanol. Then, the slides were cover-slipped using DPX mounting medium. Brainstem sections were counterstained with nuclear fast red (Vector Laboratories, Inc.) for 3 min before ethanol dehydration.
Quantification of Fos-positive neurones
At least two investigators independently quantified the number of Fos-positive neurones in a number of brain regions, including the supraoptic nucleus, paraventricular nucleus, olfactory bulb, AV3V and NTS. In the PVN, magnocellular and parvocellular regions were counted separately by comparing sections with brain atlas sections (31) . At the level counted, the parvocellular PVN includes the dorsal cap and ventromedial subdivisions. The NTS was analysed from sections spanning from rostral (bregma À12 mm) to caudal (bregma À14 mm) (31) . All of the investigators were blinded to the treatments at the time of counting. Images of the regions were acquired using a digital camera, controlled by acquisition software, and attached to an upright microscope with a 9 10 objective (Leica Microsystems, Wetzlar, Germany). Images from at least six regions from every rat in each treatment group were acquired. Using IMAGEJ (NIH, Bethesda, MD, USA), these images were converted to 8-bit, thresholded using the same parameters and Fos-positive neurones were counted using the ANALYSE PARTICLES macro. The conditions for thresholding and for the macro were determined in part by comparing the count results with manually-counted images and ensuring that the counts made manually and via IMAGEJ matched for 20 regions. The number of Fos-positive neurones within each region of interest (ROI) was normalised by the surface area of that ROI to allow comparison. Thus, the number of Fos-positive neurones in these regions is expressed as the mean AE SEM per 10 4 lm 2 (corresponding to an area of 100 9 100 lm).
The total number of Fos-positive neurones was counted for each region and is expressed as the mean AE SEM per section. Oxytocin neurones are densely packed within the SON and cell structures in the sections overlap, sometimes making it hard to distinguish between single neurones, which might affect counting Fos-positive nuclei in oxytocin stained neurones. Therefore, we also counted a proportion of clearly distinguishable oxytocin neurones and oxytocin neurones expressing Fos protein directly under the microscope (9 20 magnification in at least six regions in every rat, and the values are expressed as percentages).
In vivo microdialysis
Rats were anaesthetised with urethane (1.25 g/kg I.P.), and a cannula was implanted in the left femoral vein as described above. Rats were fixed into a stereotaxic frame and a microdialysis probe (U-shaped membrane with a molecular cut-off of 6 kDa) (32) was implanted into the right SON in accordance with the coordinates in the stereotaxic atlas by Paxinos and Watson (31) (0.6 mm caudal to bregma, 1.8 mm lateral to midline and 9.4 mm deep from the surface of the skull). The microdialysis probe was secured to the skull with two jewellers' screws and dental cement. In another experiment, to test the effect of a-MSH retrodialysis directly onto the SON on somatodendritic release, the SON was exposed by transpharyngeal surgery and a U-shaped dialysis probe was positioned with the loop of the membrane flat on the ventral surface of the SON, as described previously (33) .
The probe was connected to a microinfusion pump that perfused aCSF (NaCl 138 mM, KCI 3.36 mM, NaHCO 3 9.52 mM, Na 2 HPO 4 2H 2 O 0.49 mM, urea 2.16 mM, CaCI 2 1.26 mM, MgCl 2 6H 2 O 1.18 mM; pH 7.2) at 3 ll/min. After 2 h of microdialysis without sampling, consecutive 30-min dialysis samples were collected directly into Eppendorf vials, which were immediately kept on dry ice and stored at À80°C until assay for oxytocin.
In experiments where drugs were given I.V., MT-II (1 mg/kg) or vehicle were administered at the beginning of the fourth sample period, as shown in Fig. 1 . For experiments with I.C.V. injections, MT-II (1 lg/rat) and vehicle (aCSF) were administered at the beginning of the third or fifth microdialysis sample period. The sequence of the drug administrations was alternated between successive trials. In both experiments, aCSF containing 1 M NaCl was retrodialysed directly into the SON during the penultimate microdialysis period and switched back to normal aCSF during the last microdialysis period ( Fig. 1) . Dialysis with high NaCl medium served as a positive control to confirm the suitability of the microdialysis approach for monitoring dynamic changes in the release of oxytocin, as described previously (34) .
In one of the experiments, aCSF was changed to aCSF containing a-MSH during the third microdialysis period for 30 min. We applied a-MSH by retrodialysis, using a concentration in the dialysate of 167 ng/ll. Because dialysis membranes are only weakly permeable, the resulting extracellular concentrations are very much lower (previously estimated as three or four orders of magnitude lower) (33) .
At the end of experiments, rats were killed by an overdose of sodium pentobarbital (160 mg/kg) and their brains were removed and stored until sectioning. Coronal sections of the hypothalamus (40 lm) were used for reconstruction of the placement of the microdialysis probes. Judgment of the successful implantation of the SON was made before analysing microdialysis and plasma samples.
Blood collection
A femoral vein was cannulated for blood sampling. Blood samples (0.7 ml) were withdrawn into heparinised syringes, centrifuged, and the plasma was separated and stored at À 80°C for subsequent oxytocin radioimmunoassay. Blood cells were re-suspended in 0.9% saline and infused via the femoral cannula. The samples were taken as shown in Fig. 1 .
Radioimmunoassay
Microdialysates (90 ll) were kept at À80°C until evaporation and radioimmunological quantification of oxytocin without prior extraction. Blood samples were centrifuged (5 min at 2040 g, 4°C) and plasma samples (0.1 ml) were kept at À80°C until extraction was performed at 4°C using the appropriate procedure: 20 mg heat-activated (700°C) LiChroprep Si 60 (Merck, Darmstadt, Germany) in 1 ml of distilled water was added to each sample, mixed for 30 min and centrifuged; the pellet was then washed with double distilled water and 0.01 N acidic acid and subsequently mixed for 30 min in 60% acetone to elude the neuropeptide; the evaporated extracts were kept at À20°C. To both evaporated microdialysates (SpeedVac; Thermo Scientific, Waltham, MA, USA) and plasma extracts, respectively, 0.05 ml of assay buffer was added and oxytocin was estimated using a highly sensitive and specific radioimmunoassay (RIAgnosis, Sinzing, Germany) (35) . The assay was standardised and validated in animal and human studies using a wide variety of stimuli (hypertonicity, parturition, lactation, stress, etc.) to reliably detect unbound, bioactive oxytocin. This validation included centrally released (as measured in microdialysates and CSF) and peripherally secreted (as measured in plasma) neuropeptide. In brief, 0.05 ml of antibody (raised in rabbits against oxytocin) and, after a 60-min preincubation interval, 0.01 ml of 125 I-labelled tracer (Perkin Elmer, Rodgau, Germany) was added to each aliquot. After an incubation period of 3 days at 4°C, unbound radioactivity was precipitated by activated charcoal (Sigma-Aldrich, Hamburg, Germany). Under these conditions, an average of 50% of total counts are bound with < 5% nonspecific binding. The detection limit is in the 0.1-0.5 pg/sample range, depending on the age of the tracer, with typical displacements of 20-25% at 2 pg, 60-70% at 8 pg and 90% at 32 pg of standard neuropeptide (Sigma-Aldrich). Cross-reactivities with vasopressin, ring moieties and terminal tripeptides of both oxytocin and vasopressin and a wide variety of peptides comprising 3 (a-melanocyte-stimulating hormone) up to 41 (corticotrophin-releasing factor) amino acids are < 0.7% throughout. All evaporated microdialysates and plasma extracts to be compared were treated identically and assayed in the same batch at the same time to avoid inter-assay variability (the intra-assay variability is < 8%). Serial dilutions of plasma samples containing high levels of endogenous oxytocin run strictly parallel to the standard curve indicating immunoidentity.
In vivo electrophysiology
Male Sprague-Dawley rats were anaesthetised with an I.P. injection of urethane (1.25 g/kg); a femoral vein and the trachea were cannulated and the pituitary stalk and right SON were exposed transpharyngeally as described previously (36) . A glass micropipette (filled with 0.15 M NaCl, 20-40 MΩ) was lowered into the SON under direct visual control to record the extracellular activity of single neurones. A bipolar stimulating electrode (SNEX-200X; Clarke Electromedical Instruments, Reading, UK) was placed on the pituitary stalk and set to deliver single matched biphasic pulses (1 ms, < 1 mA peak to peak) for antidromic identification of SON neurones. Oxytocin neurones were distinguished from vasopressin neurones by their firing pattern and by their opposite response to I.V. cholecystokinin [CCK, 20 lg/kg, cholecystokinin-(26-33)-sulphated; Bachem Ltd., Saffron Walden, UK] (i.e. transient excitation of oxytocin neurones and no effect or short-term inhibition of vasopressin neurones) (37) . After a period of stable baseline recording, MT-II (1 mg/kg) was given I.V. In most neurones, recordings were made for 40 min after MT-II administration. At the end of each experiment, the rats were killed by an overdose of sodium pentobarbital (160 mg/kg, I.V.). The firing rates of neurones were interfaced to a personal computer and recorded using SPIKE2 (Cambridge Electronic Design, Cambridge, UK). Only one neurone was tested with MT-II in any rat.
Statistical analysis
The data were analysed using PRISM, version 6 (GraphPad Software Inc., San Diego, CA, USA). Fos expression experiments were analysed using a two-tailed MannWhitney test. Experiments using intranasal MT-II administration were analysed using a Kruskal-Wallis test followed by Dunn's multiple comparison test. Oxytocin content in microdialysates were analysed using two-way ANOVA with treatment and time as variables. Oxytocin content in the retrodialysis experiment was analysed using Friedman's test of repeated measures followed by Dunn's multiple comparison test. Delta changes in plasma oxytocin content in experiments, using I.V. and I.C.V. administration, were analysed by a two-tailed Mann-Whitney test and a Wilcoxon matched-pairs signed rank test, respectively.
In the electrophysiology experiments, responses to MT-II were analysed by comparing the mean firing rate in 10-min intervals after MT-II injection with the basal firing rate measured in a 10-20-min control period before MT-II injection. A 10% change in firing rate was set as threshold to categorise the cell as a responsive to MT-II. For analysis of individual responsive neurones, the firing rate in the 10-min period before MT-II injection was compared with the rate in the 10-min period after injection for oxytocin neurones, and the firing rate 20 min before MT-II was compared with that at 40 min after injection for vasopressin neurones; with both using a onetailed paired t-test, where P ≤ 0.01 was considered statistically significant. at the beginning of the third and fifth dialysis sample (arrows). The sequence of the drug administrations was alternated between the successive trials. The microdialysis medium was changed from normal aCSF (isotonic medium) to aCSF containing 1 M NaCl (hatched rectangle) during the penultimate dialysis sample. In Experiment 3, a-melanocyte-stimulating hormone (MSH) (167 ng/ll) was given through the microdialysis probe (retrodialysis, grey rectangle). Blood samples were taken at the time points as indicated (numbered circles).
The mean change in firing rate (spikes/s) in 30-s bins in the period 0-10 min after the MT-II injection was tested for whole population of oxytocin neurones to check whether this change was significantly different from 0, using a two-tailed Wilcoxon signed rank test. For vasopressin neurones, the period 0-40 min in 10-min bins after MT-II injection was tested; the longer binwidth was required because many vasopressin neurones fire phasically, and so spike counts are very variable over short binwidths. All data are reported as the mean AE SEM. P ≤ 0.05 was considered statistically significant unless otherwise stated.
Results
Effect of systemic MT-II on Fos expression
Fos, the protein product of the immediate-early gene c-fos is widely used marker of neuronal activation. In rats injected with MT-II (1 mg/kg), there was a significantly higher density of Fospositive neurones in the SON (15.8 AE 1.6 versus 7.5 AE 0.9 per 10 4 lm 2 , P ≤ 0.05) ( Fig. 2A) (Fig. 2D) . No significant change in Fos expression was observed in parvocellular regions (Fig. 2D) . Double immunohistochemistry for Fos and oxytocin revealed that both oxytocin neurones and nonlabelled, putative vasopressin neurones showed more Fos expression in rats injected with MT-II in the SON (P ≤ 0.05) (Fig. 3E) . There was also significantly more Fos expression in magnocellular and parvocellular oxytocin neurones in the PVN of rats injected with MT-II (P ≤ 0.05). There was also more Fos expression in magnocellular and parvocellular non-oxytocin neurones, although this did not achieve statistical significance (P = 0.084) (Fig. 3F) . In rats injected with MT-II, the proportion of Fos-positive oxytocin neurones was significantly higher in the SON (47.2 AE 4.8% versus 16.6 AE 3.3%, P ≤ 0.05), mPVN (48.4 AE 5.1% versus 11.4 AE 3.0%, P ≤ 0.05) and pPVN (42.0 AE 5.1% versus 10.3 AE 3.1%, P ≤ 0.05) compared to vehicle.
Central blockage of melanocortin receptors
To determine whether the Fos expression induced by MT-II was mediated by activation of central melanocortin receptors, a melanocortin antagonist was injected centrally (I.C.V.) before systemic injection of MT-II (I.V.). Rats injected with the melanocortin antagonist had significantly (P ≤ 0.05) less Fos expression in oxytocin and putative vasopressin neurones in the SON than vehicle-injected rats (Fig. 4A ) and there was a lower proportion of Fos-positive oxytocin neurones in the SON (10.8 AE 1.6% versus 33.1 AE 3.5%, P ≤ 0.05).
In the PVN, there was also significantly less MT-II induced Fos expression in both magnocellular and parvocellular oxytocin neurones in rats given I.C.V. antagonist (P ≤ 0.05), and less Fos expression in magnocellular non-oxytocin neurones, although this was not significantly different (P = 0.094) (Fig. 4B) . The proportion of oxytocin neurones that expressed Fos in antagonist-treated rats was significantly lower in both the mPVN (5.1 AE 0.9% versus 22.8 AE 4.1%, P ≤ 0.05) and in the pPVN (9.2 AE 2.1% versus 26.9 AE 5.3%, P ≤ 0.05).
The analysis of the NTS showed significantly more Fos expression in rats given an I.V. injection of MT-II than in vehicle-injected rats (P ≤ 0.05) (Fig. 5A,B) . A higher density of Fos expression was observed in the caudal part of the NTS (i.e. bregma À14 mm) (31) (Fig. 5A,  insert) . However, I.C.V. administration of the melanocortin antagonist did not affect the Fos expression induced by MT-II (Fig. 5A) .
Intravenous administration of MT-II did not significantly change Fos expression in other brain areas analysed, such as the OVLT, the SFO and the central amygdala (cAMG) (Fig. 5C) .
Effect of intranasal MT-II on Fos expression
Fos expression was not significantly different between rats exposed to intranasal administration of 1 lg or 30 lg of MT-II and rats exposed to intranasal vehicle in any of the areas analysed ( Table 1) .
Effect of MT-II on electrophysiological activity of supraoptic neurones
We tested the effects of I.V. administration of MT-II on the electrical activity of eight oxytocin neurones and eight vasopressin neurones (of which five fired phasically and three continuously) in the SON of urethane-anaesthetised rats (Fig. 6) .
Before injection of MT-II, the mean basal firing rate of the eight oxytocin neurones was 2.7 AE 0.69 spikes/s. The mean firing rate in these eight neurones was increased by 0.66 AE 0.16 spikes/s (P ≤ 0.05, Wilcoxon signed rank test) (Fig. 6B) between 2.5 and 8 min after injection. Analysing these neurones individually showed that MT-II induced a change in the firing activity that exceeded the threshold of 10% in seven of the eight neurones (Fig. 6C) . In each of these seven responsive neurones, MT-II induced a significant increase in firing rate over the 10-min period after injection (P ≤ 0.01, paired t-test).
For vasopressin neurones, we combined the recordings from five phasic-and three continuous-firing neurones and analysed the difference in their mean firing rate (in 10-min bins) before and after MT-II. Vasopressin neurones showed a heterogeneous response to MT-II. Before MT-II injection, the mean basal firing rate in the eight vasopressin neurones was 6.6 AE 0.6 spikes/s. After MT-II injection, the mean firing rate in these eight neurones was increased by 1.3 AE 0.7 spikes/s over the 40-min period after injection (Fig. 6E) ; however, the change exceeded 10% in only three of the eight neurones (Fig. 6F) and, of those three responsive neurones, only one Data are the mean AE SEM (n = 6 per group). AVP, arginine vasopressin; OT, oxytocin; PVN, paraventricular nucleus; SON, supraoptic nucleus. showed a significant increase in firing rate after MT-II (P ≤ 0.01, paired t-test). Three phasic-firing neurones showed a transient inhibitory response (approximately 2 min) in response to I.V. injection of MT-II.
Central and peripheral oxytocin secretion
Plasma samples and microdialysates were collected to determine peripheral and central oxytocin release in response to systemic or I.C.V. administration of MT-II. There was no significant change in the oxytocin content in microdialysates collected in the SON in response to MT-II either given peripherally or centrally. Direct osmotic stimulation has been used previously as a positive control to confirm correct probe placement within the SON. The osmotic stimulus resulted in a robust release of oxytocin within the SON, and this release was no different between the MT-II and vehicletreated group (Fig. 7A,C) . The change in plasma concentration of oxytocin was significantly greater (P ≤ 0.05) in rats injected with systemic MT-II (baseline 5.3 AE 1.2 pg/ml, MT-II 8.9 AE 1.3 pg/ml) compared to vehicleinjected rats (baseline 7.3 AE 2.1 pg/ml, saline 6.5 AE 1.9 pg/ml) (Fig. 7B) . Peripheral oxytocin concentrations after I.C.V. injection of MT-II (MT-II at 120 min: baseline 1.7 AE 0.2 pg/ml, aCSF 2.7 AE 1.2 pg/ml, MT-II 8.5 AE 4.7 pg/ml; vehicle at 120 min: baseline 1.6 AE 0.5 pg/ml, MT-II 5.7 AE 2.8 pg/ml, aCSF 5.3 AE 3.1 pg/ml) also tended to be increased, although this change did not reach (Fig. 7D) . Retrodialysis of hypertonic aCSF directly into the SON resulted in a robust increase in peripheral oxytocin release in both experiments, with no differences between the groups (I.V. MT-II 12.2 AE 1.5 pg/ml, I.V. saline 9.4 AE 1.2 pg/ml; I.C.V. MT-II at 120 min: 23.4 AE 2.2 pg/ml, I.C.V. vehicle at 120 min: 18.0 AE 3.6 pg/ml) (Fig. 7B,D) .
In the SON of five rats, retrodialysis of a-MSH directly onto SON neurones resulted in a significant increase of somatodendritic oxytocin release (Fig. 7E) . Oxytocin concentrations had returned to basal levels in the second period after a-MSH infusion when the retrodialysis medium was changed back to aCSF.
Discussion
The present study aimed to determine whether systemic administration of the melanocortin agonist MT-II stimulates the central oxytocin systems in rats. We showed that systemic injection of MT-II induces the expression of the immediate early gene product Fos in oxytocin neurones of the SON and the PVN, and this effect was attenuated by prior I.C.V. administration of the melanocortin antagonist SHU-9119. There was also a significant increase in Fos expression in the NTS, but not in the SFO and OVLT, comprising two circumventricular organs that receive peripheral signals and are known to modulate oxytocin and vasopressin secretion. Additionally, I.V. administration of MT-II increased the firing rate of oxytocin neurones. However, the MT-II-induced increase in Fos expression and electrical activity in SON oxytocin neurones was not coupled to detectable changes in oxytocin release in the SON.
The first evidence of a link between melanocortins and oxytocin was found by Jacobowitz and O'Donohue (38) , who reported that a-MSH fibres, originating from neurones in the arcuate nucleus, projected to the PVN. Furthermore, fibres containing adrenocorticotrophic hormone, a peptide precursor of a-MSH, were found in the PVN and SON (39) , as are fibres containing b-endorphin, another product of POMC that is co-localised with a-MSH (40) . In addition, central injections of a-MSH or MT-II increased the expression of Fos in the SON and PVN (19, 41, 42) and a recent study showed that systemic injection of MT-II increased the expression of another immediate-early gene product, EGR-1, in the PVN of prairie voles (26) . These actions are considered to be mediated by activation of MC4R, which is expressed in the PVN and SON (21, 22) .
Because a-MSH does not penetrate the BBB (23, 24) , synthetic drugs, such as MT-II, were developed as a-MSH homologue with enhanced potency and longer half-life. It is assumed that the cyclic and shorter molecular conformation of MT-II results in higher brain penetration compared to a-MSH. MT-II has been extensively used to study central and peripheral melanocortin actions, and the physiological actions of peripherally administered MT-II are considered to be, at least in part, exerted centrally (43, 44) . Trivedi et al. (45) showed that systemic injection of (125)Iodo-MT-II penetrated the brain parenchyma in low amounts; however, a high concentration of radiolabelled MT-II was bound to the circumventricular organs.
This raised the question whether the effects of MT-II in the SON and PVN described in the present study were direct or mediated indirectly by other brain structures. The SFO and OVLT are neurohemal structures located outside the BBB in which neurones can monitor and sense compounds present in the blood circulation (46) (47) (48) . Both the OVLT and the SFO express MC4R (21) and both are involved in the modulation of systemic and central vasopressin and oxytocin release by neuronal pathways that connect them with the PVN and SON (49-51) .
We did not detect any significant change in Fos expression induced by systemic MT-II administration in the OVLT or SFO, although there was a significant increase in Fos expression in neurones of the NTS, which also expresses MC4R (21) . Direct application of a-MSH has been shown to have excitatory and inhibitory effects on different subsets of NTS neurones (52) . However, the NTS receives visceral inputs through the vagal nerve to modulate gastrointestinal and cardiorespiratory functions, and melanocortins are involved in modulating these functions (53, 54) and so it may be that activation of peripheral receptors in response to i.v. MT-II administration contributed to the increased Fos expression in the NTS.
The results of the present study show that the i.c.v. administration of the melanocortin antagonist before systemic administration of MT-II reduced Fos expression induced by MT-II in the oxytocin neurones of the SON and PVN, which is consistent with the conclusion that the increase in Fos expression was mediated by activation of central receptors. The melanocortin antagonist SHU-9119 is structurally related to MT-II, competing for MC3/4R (55, 56) , and has been extensively used to reverse MT-II actions (54, 57, 58) . The lack of significant changes in Fos expression in NTS neurones after I.C.V. administration of SHU-9119 suggests that i.v. MT-II acts on peripheral targets that are subsequently signalled to the NTS. Hence, the effects of MT-II described in the present study appear to be mediated by a combination of central and peripheral effects.
The antagonist also reduced Fos expression in oxytocin-negative neurones in the magnocellular regions of the PVN. These are likely to be magnocellular vasopressin neurones, although the PVN subregions are not wholly homogeneous, and contain some non-magnocellular neurones. However, the SON contains only magnocellular neurones and so, in the present study, the attenuation of Fos expression in non-oxytocin neurones can be definitively associated with magnocellular vasopressin neurones.
Previous studies have shown that the I.C.V. application of a-MSH and a MC4R agonist resulted in a dose-dependent inhibition in the electrical activity of SON oxytocin neurones in vivo (19) . In the present study, we report that I.V. injection of MT-II increased the firing rate of oxytocin neurones in the SON, indicating that the actions of I.V. MT-II on these neurones are predominantly mediated by peripheral inputs. A possible mediator for these actions is the NTS, as suggested by our Fos results. The SON receives excitatory inputs from the NTS which are activated, for example, in response to I.V. CCK, which activates NTS neurones via vagal pathways (51, 59) .
Our electrophysiology results show a heterogeneous response of SON vasopressin neurones to I.V. injection of MT-II. The change in electrical activity observed in some vasopressin neurones is supported by our Fos study showing an increase in Fos expression in non-oxytocin cells in the SON. In some phasic-firing vasopressin neurones, we observed a transient inhibition of the electrical activity immediately after injection of MT-II. This might be a result MT-II acting at the cardiovascular system because systemic administration of MT-II increased heart rate and blood pressure in a dose-dependent fashion in anaesthetised and conscious mice, even at lower doses (54) than the dose administered in the present study. Increases in blood pressure have been shown to transiently inhibit phasic vasopressin neurones in rats (60, 61) .
In oxytocin neurones, electrical activity is coupled to the secretion of oxytocin into the blood, although this is not always accompanied by the release of oxytocin from the somatodendritic compartment (15, 17) . Direct application of a-MSH to SON explants in vitro stimulates dendritic oxytocin release (19) but, in the present study, although plasma oxytocin levels were significantly increased in response to systemic MT-II, in vivo microdialysis in the SON did not detect changes in somatodendritic oxytocin release. Similarly, Modi et al. (26) failed to detect an increase in oxytocin release in the nucleus accumbens following I.P. administration of MT-II in prairie voles.
Because systemic administration of MT-II did not trigger somatodendritic oxytocin release, we applied MT-II directly into the brain (I.C.V.). Again we did not detect any changes in somatodendritic oxytocin release from SON neurones in response to MT-II. Previously, we have shown that a-MSH triggers dendritic oxytocin release in vitro (SON explants) and, in the present study, we show that retrodialysing a-MSH directly into the SON increases somatodendritic release in vivo. By contrast to axonal oxytocin release, somatodendritic release involves a transient increase in intracellular calcium ( channels from the N-type appear to play a major role in the regulation of somatodendritic oxytocin release from SON explants (63) . However, in other systems, such as transfected HEK293 cells and cultured mouse amygdala neurones, activation of MC4R by MT-II has been reported to inhibit N-type Ca 2+ channels (64) .
Recently, it was suggested that intranasal administration can bypass the BBB to deliver drugs directly into the brain (65) , although this is very controversial (11) . It has been suggested that peptides might be taken up by olfactory or trigeminal neurones, and then be axonally transported and released into the brain. Peptides 'might pass through intercellular clefts into the subarachnoid space, although transport across the arachnoid membrane is not an important route for the entry of solutes into brain' (11) . MC3R and MC4R (66, 67) are expressed in the rat olfactory bulb, suggesting that this region is a target for melanocortins, and changes in gene expression and behaviour following intranasal administration of melanocortin receptor ligands have been reported (68, 69) . However, we found that MT-II administered intranasally at two different doses did not induce any changes in Fos expression, neither in the olfactory bulbs, nor in any of the other brain regions that we analysed. It thus appears that, in rats, intranasal MT-II, similar to vasopressin and oxytocin (29), does not reach the brain at sufficient levels to trigger Fos expression. Whether the previously described effects are mediated indirectly by peripheral actions or whether some of the MT-II given in very high doses can leak through the BBB to act via receptors located in the olfactory bulb remains to be shown.
In recent years, administration of oxytocin has been proposed for the treatment of neuropsychiatric disorders. The enhancement of central oxytocin systems by melanocortins has been proposed as a potential therapeutic approach, and several melanocortin analogues are under development for the treatment of central and peripheral disorders in humans. However, in the present study, we failed to detect changes in oxytocin release in the SON following I.V. administration of MT-II. Finally, the increased expression of Fos protein and electrical activity suggests that the main actions of I.V. MT-II are mediated indirectly.
